Details of the Drug Combination

General Information of Drug Combination (ID: DCY71Q9)

Drug Combination Name

NITD609 OZ277

Indication

Disease Entry	Status	REF
DD2	Investigative	[1]

Component Drugs

NITD609 DMQHBSX

OZ277 DM1YB0R

Small molecular drug

2D MOL

3D MOL

High-throughput Screening Result

Testing Cell Line: DD2

Zero Interaction Potency (ZIP) Score: 1.077

Bliss Independence Score: 2.23

Loewe Additivity Score: 0.045

LHighest Single Agent (HSA) Score: 1.541

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of NITD609

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Phase 2	[2]

NITD609 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Voltage-gated potassium channel Kv11.1 (KCNH2)	TTQ6VDM	KCNH2_HUMAN	Inhibitor	[4]
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[4]
------------------------------------------------------------------------------------

Indication(s) of OZ277

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Approved	[3]

OZ277 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A)	TTZVSJ2	NOUNIPROTAC	Inhibitor	[3]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	ClinicalTrials.gov (NCT01836458) A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection. U.S. National Institutes of Health.
3	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
4	Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.